Evidence map›Paper›PMID 28484458›Full record

ArticleFrontiers in immunology2017

Use of Lentiviral Particles As a Cell Membrane-Based mFasL Delivery System for

José M Rodríguez-Frade, Anabel Guedán, Pilar Lucas, Laura Martínez-Muñoz, Ricardo Villares, Gabriel Criado, Dimitri Balomenos, Hugh T Reyburn, Mario Mellado

Abstract read
In one paragraph

Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

José M Rodríguez-FradeDepartment of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, Madrid, Spain.
Anabel GuedánDepartment of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, Madrid, Spain.
Pilar LucasDepartment of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, Madrid, Spain.
Laura Martínez-MuñozDepartment of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, Madrid, Spain.
Ricardo VillaresDepartment of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, Madrid, Spain.
Gabriel CriadoInflammatory and Autoimmune Diseases Group, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain.
Dimitri BalomenosDepartment of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, Madrid, Spain.
Hugh T ReyburnDepartment of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, Madrid, Spain.
Mario MelladoDepartment of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During budding, lentiviral particles (LVP) incorporate cell membrane proteins in the viral envelope. We explored the possibility of harnessing this process to generate LVP-expressing membrane proteins of therapeutic interest and studied the potential of these tools to treat different pathologies. Fas-mediated apoptosis is central to the maintenance of T cell homeostasis and prevention of autoimmune processes. We prepared LVP that express murine FasL on their surface. Our data indicate that mFasL-bearing LVP induce caspase 3 and 9 processing, cytochrome C release, and significantly more cell death than control LVP

Indexed as

apoptosiscaspasesFasLlentiviral particlesrheumatoid arthritis

Identifiers

PMID28484458
PMCPMC5399037

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.